Selective laser trabeculoplasty for the treatment of intraocular pressure elevation after viscocanalostomy with Ologen implant in the management of primary open-angle glaucoma: a retrospective cohort study

选择性激光小梁成形术治疗粘小管成形术后Ologen植入物治疗原发性开角型青光眼引起的眼压升高:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: Selective laser trabeculoplasty (SLT) is a non-invasive treatment option for glaucoma. It uses a Q-switched Nd: YAG laser. The aim of this study was to evaluate the efficacy of SLT as a treatment option for eyes with primary open-angle glaucoma (POAG) that have previously undergone viscocanalostomy with an Ologen implant, displaying uncontrolled intraocular pressure (IOP). METHODS: This retrospective cohort study included 26 eyes of 26 patients with POAG who had had SLT after viscocanalostomy or phacoviscocanalostomy with Ologen implant. These eyes showed a progression of glaucomatous damage, the IOP was above 21 mmHg, or with intolerable glaucoma medications. SLT was done using Tango Reflex multimodality YAG/SLT laser which is a Q-switched Nd: YAG laser producing a single 532 nm wavelength pulse with a 400 mm spot size and 3 ns pulse duration. The follow-up period was one year. RESULTS: One year post-SLT, complete success was achieved in 19 cases (73.1%), qualified success in 4 cases (15.4%), and failure in 3 cases (11.5%). The mean decrease in IOP was 5.64 ± 4.05 mmHg, the mean reduction of antiglaucoma medications was 1.00 ± 0.85, and the mean percentage of reduction in IOP was 23.5 ± 16.4. There was a statistically significant decrease in IOP and antiglaucoma medications (p = < 0.01). CONCLUSION: SLT is a simple and effective procedure that can be used as a treatment option for eyes with POAG after viscocanalostomy with Ologen implant to reach the target IOP and decrease the number of antiglaucoma medications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。